Going to the grassroots level

Chen Zhihui, deputy director of the Zhejiang Provincial Drug Administration, went to Anji to carry out the “three services” activities, and went deep into the bio-pharmaceutical companies such as Zhejiang Huaduan Pharmaceutical Co., Ltd. to conduct on-the-spot investigations and listen to the development plan of the enterprise demand.

At the same time, it also proposed to guide the healthy development of enterprises and the construction of biomedical platforms. The training and introduction of talents requires the provincial bureau to give priority guidance and support to promote the healthy development of the Anji biomedical industry. Gao Liugen, Chairman of Zhejiang Huashang Pharmaceutical Group Co., Ltd. and other relevant responsible persons attended the symposium. At the meeting, he introduced the history, current situation and future planning of the company's development to the leaders, and reported on the China Pharmaceutical Group. The progress of the construction of the Anji Biomedical Industrial Park since the entry into Anji in July 2017 and the policy confusion encountered.

After listening to the introduction of the representatives of Anji County Bureau and bio-pharmaceutical enterprises, Mr. Chen and his entourage realized how to quickly and reasonably and legally realize the commissioning of biomedical products under the system of drug listing and licensing holders encountered by enterprises; how to speed up and clarify new Product research and development ideas; how to understand the spirit of the drug substance registration system and the related review of preparations, and seize the development opportunities and other issues to conduct in-depth discussions, starting from the actual situation of enterprises, for enterprises to seek a healthy development path.

In order to further understand the development of the company, in the afternoon, Director Chen and his team braved the wind and rain and went to the Zhejiang Bio-Pharmaceutical Group Co., Ltd. Anji Biomedical Industrial Park for in-depth field visits. After listening to the report and on-site inspection, Director Chen and other officials gave full affirmation to the overall appearance, construction progress and development planning of the industrial park. At the same time, they also welcomed the deepening of the development of the province with the provincial, municipal and county bureaus. Communicate to help the healthy development of the company.

Established in June 2017, Zhejiang Huadi Pharmaceutical Group Co., Ltd. is a holding subsidiary of Hangzhou Huaduan Group Co., Ltd., which is mainly engaged in the research and development and production of biopharmaceuticals, pharmaceutical intermediates and health products, especially in animal protein peptide extraction. It has an internationally leading technical level in the research and development and industrialization of nucleic acid drugs and health products. On July 19, 2018, the group became a drug marketing license holder for hepatocyte growth factor enteric-coated capsules (national new drugs, exclusive products nationwide) and transfer factor capsules. At present, the company has completed the construction of new drug production lines and quality control systems. Apply for the above varieties and carry out GMP certification.

The leaders of the provinces, municipalities, and county bureaus held symposiums on the one hand to understand the needs of enterprises, and at the same time, in-depth field visits and guidance within the enterprises were the embodiment of the “three services” activities of the competent departments of drug supervision, and they also took the grassroots level and solved difficulties. And the actual embodiment of the enterprise; it is the support and relationship to the development of Anji Biomedical Industry, and it is also a great support and encouragement to the China Pharmaceutical Group.